Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
OPL-002 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| OPL-002 SDD 20 mg | EXPERIMENTAL | 20 mg SDD formulation of OPL-002 |
| OPL-002 5 mg Tablet | EXPERIMENTAL | 5 mg tablet formulation of OPL-002 |
| OPL-002 20 mg Tablet | EXPERIMENTAL | 20 mg tablet formulation of OPL-002 |
| Name | Type | Description |
|---|---|---|
| OPL-002 | DRUG | Spray dried dispersion and tablet formulation |
Inclusion Criteria: * Male or female (of non-childbearing potential only) between 18 and 55 years of age. * Females must be of non-childbearing potential and must have undergone one of the following sterilization procedures, and have official documentation, at least 6 months prior to the first dose...
OPL-002 is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development, with a completed trial assessing its pharmacokinetics and dose proportionality. The drug is not approved for any indication and remains under investigation.
OPL-002 is being developed by Ventyx Biosciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker VTYX. The company is conducting early-stage clinical research on this small molecule in healthy volunteers.
OPL-002 is in Phase 1 clinical development. A single Phase 1 study has been completed, involving 12 healthy volunteers in the United Kingdom. The drug remains investigational and has not been approved by regulatory authorities.
OPL-002 has one completed clinical trial, NCT04451811, titled 'A PK Dose Proportionality Study of OPL-002 in Healthy Volunteers.' This Phase 1 study enrolled 12 healthy adults aged 18 years and older in the United Kingdom and was a controlled, randomized trial.
OPL-002 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The only completed trial was a pharmacokinetic study in healthy volunteers, and the drug has not yet progressed to later-stage trials or regulatory submission.